SCHEDULE 13G: Frazier Life Sciences Funds Disclose 5.1% Passive Stake in Mereo BioPharma Group plc
Beneficial Ownership Report
Frazier Life Sciences Public Fund, L.P. and affiliated entities, along with key individuals, have disclosed a collective beneficial ownership of 5.1% in Mereo BioPharma Group plc, held for passive investment purposes.
Summary
- Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., and FHMLSP, L.L.C. collectively beneficially own 27,578,325 Ordinary Shares of Mereo BioPharma Group plc, representing 3.5% of the class.
- Frazier Life Sciences Public Overage Fund, L.P., FHMLSP Overage, L.P., and FHMLSP Overage, L.L.C. collectively beneficially own 7,509,280 Ordinary Shares, representing 0.9% of the class.
- Frazier Life Sciences X, L.P., FHMLS X, L.P., and FHMLS X, L.L.C. collectively beneficially own 1,590,155 Ordinary Shares, representing 0.2% of the class.
- Frazier Life Sciences XI, L.P., FHMLS XI, L.P., and FHMLS XI, L.L.C. collectively beneficially own 3,671,555 Ordinary Shares, representing 0.5% of the class.
- Individuals James N. Topper and Patrick J. Heron each report shared beneficial ownership of 40,349,315 Ordinary Shares, equating to 5.1% of the class, aggregating their interests across the various Frazier Life Sciences funds.
- Individuals Albert Cha and James Brush each report shared beneficial ownership of 35,087,605 Ordinary Shares, equating to 4.4% of the class.
- Individual Daniel Estes reports shared beneficial ownership of 3,671,555 Ordinary Shares, equating to 0.5% of the class.
- The percentages are calculated based on 795,001,444 Ordinary Shares outstanding on March 25, 2025, as reported in Mereo BioPharma Group plc's Annual Report on Form 10-K filed on March 26, 2025.
- The filing explicitly states that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of the issuer, indicating a passive investment stance.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership, not a performance report or strategic announcement, thus it carries a neutral sentiment.
Future Outlook
NA
Industry Context
Mereo BioPharma Group plc operates within the biotechnology and pharmaceutical industry. The filing indicates continued investment by Frazier Life Sciences, a prominent investment firm specializing in the life sciences sector, suggesting ongoing investor interest in the biopharma space.
Stakeholder Impact
- Informs shareholders and the broader market about a significant passive ownership stake held by a group of investment funds and individuals associated with Frazier Life Sciences.
Key Dates
| Date | Description |
|---|---|
| 03/25/2025 | Date of Ordinary Shares outstanding calculation (795,001,444 shares). |
| 03/26/2025 | Date of Issuer's Annual Report on Form 10-K filing, which provided the outstanding share count. |
| 04/01/2025 | Date of event which requires the filing of this statement. |
| 04/04/2025 | Date of filing of the Schedule 13G and Joint Filing Agreement. |
Keywords
Mereo BioPharma Group plc, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, SEC Filing, Biotechnology, Life Sciences, Investment Fund, Ordinary Shares, American Depository Shares, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.